表紙
市場調査レポート

花粉症:パイプライン分析

Pollen Allergy - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321938
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
花粉症:パイプライン分析 Pollen Allergy - Pipeline Review, H2 2015
出版日: 2015年09月23日 ページ情報: 英文 106 Pages
概要

花粉症の症状は、蕁麻疹や赤み、腫れなどの皮膚の反応や、口とのどの周辺の痒み、ヒリヒリした痛み、下痢、胃痛、吐き気あるいは嘔吐などの消化器の異常、のどが締め付けられる感覚、息切れ、喘鳴、鼻水などがあります。素因としては、年齢、家族歴、他のアレルギー反応などが挙げられます。治療には抗ヒスタミン剤系の薬剤を処置します。

当レポートでは、花粉症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

花粉症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Allergy Therapeutics plc
  • Anergis SA
  • Biomay AG
  • BioTech Tools s.a.
  • Circassia Pharmaceuticals plc
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Japan Tobacco Inc.
  • Laboratorios LETI S.L.
  • REGiMMUNE Corporation
  • Roxall Medizin GmbH
  • Stallergenes S.A.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ALK Birch Pollen Vaccine
  • AllerG
  • Allergen Extract Of Phleum Pratense
  • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis
  • AllerJ
  • AllerT
  • Avanz Phleum Pratense
  • Birch-SPIRE
  • BM-31
  • BM-32
  • clustoid wiesenlieschgras
  • Drug for Birch Pollen Allergy
  • Drug for Japanese Cedar Pollen Allergy
  • Drugs for Cedar Pollen Allergy
  • gpASIT + TM
  • grass allergy vaccine
  • Grass-SPIRE
  • Japanese cedar hypoallergenic vaccine
  • JCC-LAMP-Vax
  • JRC-LAMP-Vax
  • MC-LAMP-Vax
  • Multi-LAMP-Vax
  • PL-102
  • Pollinex Quattro Grass
  • Pollinex Quattro Japanese Cedar
  • Pollinex Quattro Tree
  • rBet v1
  • rBet v1-FV
  • RGI-1001
  • timothy grass pollen allergen extract
  • TO-206
  • Vaccine for Cedar Pollen Allergy
  • Vaccine for Cedar Pollen Allergy
  • Vaccine for Pollen Allergy

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7086IDB

Summary

Global Markets Direct's, 'Pollen Allergy - Pipeline Review, H2 2015', provides an overview of the Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pollen Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pollen Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pollen Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Pollen Allergy - Overview
    • Pipeline Products for Pollen Allergy - Comparative Analysis
  • Pollen Allergy - Therapeutics under Development by Companies
  • Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
  • Pollen Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pollen Allergy - Products under Development by Companies
  • Pollen Allergy - Products under Investigation by Universities/Institutes
  • Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma Joachim Ganzer KG
    • Allergy Therapeutics Plc
    • Anergis SA
    • Biomay AG
    • BioTech Tools s.a.
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Immunomic Therapeutics, Inc.
    • Japan Tobacco Inc.
    • Laboratorios LETI S.L.
    • REGiMMUNE Corporation
    • Roxall Medizin GmbH
    • Shionogi & Co., Ltd.
    • Stallergenes S.A.
  • Pollen Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerG - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen Extract for Grass Pollen Allergy, Asthma and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerJ - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AllerT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Birch-SPIRE - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-31 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-32 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clustoid wiesenlieschgras - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • grass hypoallergenic vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • japanese cedar hypoallergenic vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JCC-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MC-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multi-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Japanese Cedar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Tree - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1-FV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGI-1001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-555739 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STG-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Timothy Grass Pollen Allergen Extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TO-206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pollen Allergy - Recent Pipeline Updates
  • Pollen Allergy - Dormant Projects
  • Pollen Allergy - Discontinued Products
  • Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
      • Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
      • Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
      • Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
      • Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
      • Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
      • Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
      • Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32
      • Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
      • Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pollen Allergy, H2 2015
  • Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2015
  • Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015
  • Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2015
  • Pollen Allergy - Pipeline by Anergis SA, H2 2015
  • Pollen Allergy - Pipeline by Biomay AG, H2 2015
  • Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2015
  • Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015
  • Pollen Allergy - Pipeline by HAL Allergy BV, H2 2015
  • Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2015
  • Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2015
  • Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2015
  • Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2015
  • Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2015
  • Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H2 2015
  • Pollen Allergy - Pipeline by Stallergenes S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2015
  • Pollen Allergy - Dormant Projects, H2 2015
  • Pollen Allergy - Dormant Projects (Contd..1), H2 2015
  • Pollen Allergy - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Pollen Allergy, H2 2015
  • Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top